Sihuan Pharma Subsidiary Xuanzhu Biopharm’s Anaprazole Meets Primary Endpoint in Phase III Esophagitis Trial

• Sihuan Pharmaceutical subsidiary Xuanzhu Biopharm's anaprazole sodium met the primary endpoint in a Phase III reflux esophagitis trial, demonstrating noninferiority to rabeprazole sodium.
• Week 8 healing rates in the full analysis set were 88.4% for anaprazole versus 84.6% for rabeprazole.
• Per-protocol healing rates reached 93.9% versus 89.4% at Week 8; the trial enrolled 500 patients with moderate-to-severe erosive esophagitis.
• All treatment-related adverse events were Grade 1–2, with no Grade 3 or higher drug-related events reported.
• The new drug application for reflux esophagitis has been accepted; anaprazole received Chinese marketing approval for duodenal ulcers in June 2023.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261021-12378598), on October 21, 2026, and is solely responsible for the information contained therein.